Navigation Links
Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Johnson & Johnson Bid to Keep Clinical Studies Under Seal
Date:12/3/2013

New York, New York (PRWEB) December 03, 2013

Hundreds of Risperdal lawsuits (http://www.risperdallawsuitcenter.com/), including many that allege a link between Risperdal and gynecomastia (male breast growth), continue to move forward in a consolidated litigation underway in the Pennsylvania Court of Common Pleas in Philadelphia. According to a Motion filed on November 26, 2013, Johnson & Johnson has asserted that plaintiffs are improperly seeking to publicly release data concerning some Risperdal clinical studies. The studies, which were sealed via a court order in 2011, are exempt from public access because they were never filed with the court, or determined to be public records, the Motion states. (In Re: Risperdal Litigation, Case Number 100300296)

“Our Firm has heard from a number of individuals who are concerned about a possible connection between Risperdal and gynecomastia. We look forward to more progress in the Risperdal litigation underway in Pennsylvania,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently evaluating Risperdal lawsuits on behalf of men and boys who may have developed gynecomastia due to their use of the drug.

Risperdal and Gynecomastia
Risperdal is an antipsychotic medication that has been on the market since 1993, and is used to treat a number of psychiatric ailments in adults and children. According to court documents, Plaintiffs who have filed claims alleging a connection between Risperdal and Gynecomastia also allege that Johnson & Johnson concealed this association and improperly marketed the drug for use in children. In October 2012, Bloomberg.com reported that Johnson & Johnson had agreed to settle five Risperdal lawsuits filed in the Pennsylvania litigation involving gynecomastia allegations.*

On November 4th, the U.S. Department of Justice announced it had reached an agreement with Johnson & Johnson and its Janssen Pharmaceuticals unit to settle criminal and civil charges regarding the marketing of Risperdal and other drugs. According to court documents filed in the case, federal prosecutors had alleged that the company knew of the possible association between Risperdal and gynecomastia. The government also charged that Johnson & Johnson and Janssen marketed Risperdal for pediatric uses long before the drug was approved for such indications. Under the settlement, Johnson & Johnson will pay a total of $2.5 billion in criminal and civil penalties. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)

Alleged victims of Risperdal and gynecomastia may be entitled to compensation for any damages related to their injuries, including medial bills, lost wages, pain and suffering, and emotional distress. To learn more about the possible association between Risperdal and male breast growth, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.

*Bloomberg.com/news/2012-10-04/johnson-johnson-agrees-to-settle-five-rispersal-suits.html, Bloomberg.com, October 10, 2012

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author

Read the full story at http://www.prweb.com/releases/risperdal-lawsuit/risperdal-gynecomastia/prweb11389821.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Federal Award to Risperdal Whistleblower
2. As Risperdal Lawsuits Move Forward, Bernstein Liebhard LLP Launches Website to Provide Information Regarding Alleged Association Between Risperdal and Gynecomastia
3. Plaintiffs in 77 Risperdal Gynecomastia Lawsuits File Motion to Force J&J to Comply with Existing Settlement Agreement, Reviewed By Wright & Schulte LLC
4. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Release of Emails from Johnson & Johnson’s Janssen Subsidiary in Federal Risperdal Settlement
5. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Mounting Claims Involving Risperdal Gynecomastia Allegations in Pennsylvania Litigation
6. Risperdal Lawsuit News: Rottenstein Law Group LLP Comments on $2 Billion Risperdal Settlement Report
7. J&J to Pay $2.2B to Settle Allegations Over Its Marketing of Risperdal; Parker Waichman LLP Applauds Efforts of Whistleblowers in Helping Compel Resolution
8. Risperdal Lawsuit News: Johnson & Johnson To Pay Over $2.2 Billion In Risperdal and Invega Settlement Draws Comment From Wright & Schulte LLC
9. Risperdal Lawsuits: $2.2 Billion Settlement Between Federal Government, Johnson & Johnson Over Alleged Illegal Marketing of Risperdal, Other Medications
10. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Settlement in Risperdal Marketing Investigation
11. New Risperdal Lawsuit Filed in Pennsylvania Litigation; Alleges Male Breast Growth Injuries Caused by Anti-Psychotic Medication, Bernstein Liebhard LLP Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative ... National Family Partnership and the Drug Enforcement Administration as part of the National Red ... 10 winning schools who decorated their campuses with this year’s Red Ribbon Week theme: ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... they now offer a comprehensive in-house dental plan for all patients. Understanding that ... a plan that gives patients a number of perks, including discounts on many ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... Deloitte Wisconsin 75, an annual ranking and recognition of the largest closely held ... list, having ranked from 2008-2016. In addition, Standard Process was awarded the Talent ...
(Date:11/30/2016)... ... November 30, 2016 , ... Center For ... announced the opening of a new residential mental health treatment program in Chino ... issues such as severe anxiety, depression, bi-polar disorder, and other related issues. , ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... and stylish design wanted by today’s consumers at an affordable price, is now ... says the new watch is “a game changer” when it comes to the ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2016 bioLytical Laboratories, un líder mundial en test rápidos ... HIV Self Test , a los miembros de la Kenya Pharmaceutical Association. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical fue invitada por la ...
(Date:12/2/2016)... GARDENS, N.Y. , Dec. 2, 2016  LifeVac, ... will be included in the Emergency Response Training and ... are very excited to have LifeVac become part of ... Lih , Founder and CEO of LifeVac. "Having an ... LifeVac safely and effectively will help leverage our efforts ...
(Date:12/2/2016)... India , December 2, 2016 ... report "In Vitro Diagnostics/IVD Market by Product (Instruments, ... Hematology), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) ... global market is valued at USD 60.22 Billion ... at a CAGR of 5.5% during the forecast ...
Breaking Medicine Technology: